Gen1E Lifesciences Inc is a clinical-stage, phase 2 company based in Palo Alto, CA, specializing in the development of first-in-class therapies for inflammatory rare diseases. With a focus on unprecedented efficiency, Gen1E has accelerated from early discovery to phase 2 in just 2.5 years, utilizing their unique pipeline and AI platform.
Addressing the urgent need for innovative approaches in molecular medicine, Gen1E's differentiated solutions include the discovery of new binding pockets and a unique validated mechanism of action for treating inflammation. Their rich database and machine learning models enable the rapid development of novel compounds, unlocking a $100 billion market opportunity in respiratory, neurodegenerative, nephrology, musculoskeletal, and dermatology diseases.
Generated from the website